Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation

Preventive treatment of focal and segmental glomerusclerosis (FSGS) allograft recurrence in high risk recipients having a prior history of graft loss caused by FSGS recurrence is still a challenging question. We retrospectively identified four patients who underwent a second renal transplantation because of recurrent FSGS and who received Rituximab therapy as a prophylactic treatment. Loss of their first allograft was directly related to an early (<3 months) recurrence of FSGS that was either resistant to plasmapheresis therapy in two cases or had escaped to this therapeutic management in the two others. After the second renal transplantation, all patients were free of FSGS recurrence during follow‐ups that were between 12 and 54 months long. These preliminary results demonstrate for the first time that Rituximab therapy may constitute an attractive prophylactic option for patients being considered for a second renal transplantation because of recurrent FSGS in their first graft.

[1]  E. Salido,et al.  Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis , 2011, Nature Medicine.

[2]  M. Rastaldi,et al.  Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis , 2011, Science Translational Medicine.

[3]  C. Ponticelli,et al.  Posttransplant recurrence of primary glomerulonephritis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[4]  V. Savin,et al.  Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[5]  T. Wada,et al.  Successful treatment of recurrent focal segmental glomerulosclerosis after renal transplantation by lymphocytapheresis and rituximab , 2010, Transplant international : official journal of the European Society for Organ Transplantation.

[6]  G. Canaud,et al.  Therapeutic approach to focal and segmental glomerulosclerosis recurrence in kidney transplant recipients. , 2010, Transplantation reviews.

[7]  C. Ponticelli.  Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  D. Fischer,et al.  Nephrotic syndrome and rituximab: facts and perspectives , 2009, Pediatric Nephrology.

[9]  M. Cavazzana‐Calvo,et al.  Intensive and Prolonged Treatment of Focal and Segmental Glomerulosclerosis Recurrence in Adult Kidney Transplant Recipients: A Pilot Study , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  L. Rostaing,et al.  Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. , 2007, Clinical nephrology.

[11]  M. Pescovitz,et al.  Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. , 2006, The New England journal of medicine.

[12]  M. Pescovitz.  Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  F. Roudot-thoraval,et al.  Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  A. Monaco,et al.  Preemptive Plasmapheresis and Recurrence of FSGS in High‐Risk Renal Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  G. Ghiggeri,et al.  New Insights into the Pathogenesis and the Therapy of Recurrent Focal Glomerulosclerosis , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  M. Baum.  Outcomes after renal transplantation for FSGS in children , 2004, Pediatric transplantation.

[17]  D. Sahali,et al.  [Recent approaches to the pathogenesis of minimal change nephrotic syndrome]. , 2003, Nephrologie.

[18]  E. Jones,et al.  Recurrence of glomerulonephritis following renal transplantation. Scientific Advisory Board of the ERA-EDTA Registry. European Renal Association-European Dialysis and Transplant Association. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  S. Swan,et al.  Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. , 1996, The New England journal of medicine.

[20]  E. Ingulli,et al.  Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children--a single-center experience. , 1991, Transplantation.